Roche Bets on Recursion AI to Develop Neuroscience Drugs, Exploring New AI-Driven Drug Development Pathways

Deep Tide TechFlow reports that on August 6, according to Bloomberg, Roche announced a partnership with AI drug development company Recursion, betting on artificial intelligence technology to develop new drugs in the field of neuroscience. This is one of the industry's pioneering attempts to advance drug development using AI-driven methods. The backdrop is the longstanding challenge in neuroscience of unclear disease causes—researchers still do not fully understand the mechanisms behind diseases such as Alzheimer's and Parkinson's, leading pharmaceutical companies to repeatedly target the same set of biological targets, with most attempts ending in failure. The new generation of AI companies believes that leveraging AI technology could break through this bottleneck and significantly reduce drug trial failure rates.